2024
Evolving Concepts in Pathophysiology, Screening, and Prevention of Type 1 Diabetes: Report of Diabetes Mellitus Interagency Coordinating Committee Workshop.
Greenbaum C, Nepom G, Wood-Heickman L, Wherrett D, DiMeglio L, Herold K, Krischer J. Evolving Concepts in Pathophysiology, Screening, and Prevention of Type 1 Diabetes: Report of Diabetes Mellitus Interagency Coordinating Committee Workshop. Diabetes 2024, 73: 1780-1790. PMID: 39167668, PMCID: PMC11493760, DOI: 10.2337/dbi24-0020.Peer-Reviewed Original ResearchConceptsType 1 diabetesClinical trialsType 1 Diabetes TrialNetEtiology of type 1 diabetesImmune Tolerance NetworkFood and Drug AdministrationU.S. Food and Drug AdministrationNational Institute of DiabetesDigestive and Kidney DiseasesMultiple immune pathwaysDisease-modifying therapiesMechanism of actionTherapeutic responsePrognostic markerKidney diseaseDrug AdministrationTrialNetClinical diagnosisImmune pathwaysDiabetesTeplizumabRegulatory approvalClinical carePathophysiologyDisease
2023
Teplizumab and ÎČ-Cell Function in Newly Diagnosed Type 1 Diabetes
Ramos E, Dayan C, Chatenoud L, Sumnik Z, Simmons K, Szypowska A, Gitelman S, Knecht L, Niemoeller E, Tian W, Herold K. Teplizumab and ÎČ-Cell Function in Newly Diagnosed Type 1 Diabetes. New England Journal Of Medicine 2023, 389: 2151-2161. PMID: 37861217, DOI: 10.1056/nejmoa2308743.Peer-Reviewed Original ResearchConceptsC-peptide levelsB cell functionDiagnosed type 1 diabetesType 1 diabetesSecondary end pointsEnd pointsMild cytokine release syndromePeak C-peptide levelsMonoclonal antibodies to CD3Stimulated C-peptide levelsNewly diagnosed type 1 diabetesClinical type 1 diabetesCytokine release syndromePatients 8 yearsPlacebo-controlled trialPrimary end pointAntibodies to CD3Clinical end pointsAssociated with administrationPrevent disease progressionGlycated hemoglobin levelsFood and Drug AdministrationTarget glucose rangeT cellsTeplizumab
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply